Research Progress
Mar. 2020 - Award: Hong Fang (clinical fellow) receives CAPA-GoPath Best Abstract Award, 1st Place, at USCAP-2020, Feb. 29-Mar. 4, 2020, Los Angeles, CA for "MDS with t(6;9)/DEK-NUP214" (USCAP platform presentation)
Jul. 2019 – Editorial Board: Shimin Hu joins the Editorial Board of Frontiers in Oncology as an Associate Editor for Hematologic Malignancies
Mar. 2018 - Highlight: JNCCN highlights Zimu Gong's paper on cytogenetics-based risk prediction of blastic transformation of CML.
Feb. 2018 – Editorial Boards: Shimin Hu joins the Editorial Boards of American Journal of Clinical pathology and Leukemia Research
Dec. 2017 – Publication: Habibe Kurt (clinical fellow) publishes paper "Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome" in Modern Pathology.
Dec. 2017 - Publication: Zimu Gong publishes paper "Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors" in Blood Advances.
Nov. 2017 - Award: Zimu Gong (visiting PhD student) receives ASH Abstract Achievement Award, 59th ASH Annual Meeting, Atlanta, GA for "Prediction of blastic transformation of CML" (ASH oral presentation)
Jul. 2017 - Publication: Zimu Gong publishes paper "Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia" in Blood Cancer Journal.
May 2017 – Award: Zhihong Hu (clinical fellow) receives The Shannon Timmins Fellowship for Leukemia Research, The University of Texas MD Anderson Cancer Center, May 3, 2017
Mar. 2017 - Publication: Zi Chen (visiting associate professor) publishes paper "Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy" in Leukemia.
Sept. 2016 - Highlight: MD Anderson Cancer Center spotlights Zi Chen's paper on cytogenetic landscape of CML-BP.
Oct. 2016 - Highlight: iCMLf highlights Zi Chen's paper on cytogenetic landscape of CML-BP.
Feb. 2017 - Publication: Zi Chen publishes paper "Differential depth of treatment response required for optimal outcome in blast phase versus chronic phase of chronic myeloid leukemia" in Blood Cancer Journal. This study could provide a basis for establishing a guideline in the management of patients with CML-BP.
Jul. 2016 - Publication: Zi Chen publishes paper "Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy" in Leukemia.
May 2016 - Publication: Zi Chen publishes paper "Differential clinical and prognostic impact of myeloid sarcoma versus medullary myeloid blast phase in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy" in Blood Cancer Journal.
Jun. 2016 - Award: Kristina Regimi (MS student) receives 2016 AGT Student Research Award at AGT 41st Annual Meeting, June 23-25, 2016, Orange County, CA for "MYC rearrangement in PCM" (only one student awarded nationally every year).
Jun. 2016 – Publication: Wei Wang (clinical fellow) publishes paper "Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy" in Blood.
Jun. 2016 - Highlight: Blood highlights Wei Wang's paper on risk stratification of CML.
Apr. 2016 - Highlight: iCMLf highlights Wei Wang's paper on risk stratification of CML.
May 2016 – Award: Wei Wang receives The Kimberly Patterson Endowed Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center, May 20, 2016.
Mar. 2016 - Award: Wei Wang receives CAPA-GoPath Best Abstract Award, 1st Place, at USCAP-2016, March 12-18, 2016, Seattle, WA for "Risk Stratification of CML".
Jan. 2016 - Award: Wei Wang receives Platform Competition, 1st Place at Texas Society of Pathologists Annual Meeting, Jan 17, 2016, Dallas, TX for "Risk Stratification of CML".
Nov. 2015 - Publication: Wei Wang publishes paper "Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors" in Leukemia.
Oct. 2015 – Publication: Wei Wang publishes paper "Clinical and prognostic significance of 3q26.2 rearrangements and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors" in Blood.
Oct. 2015 - Highlight: MDedge Hematology News highlights Wei Wang's paper on 3q26.2 rearrangement in CML.
Oct. 2015 - Highlight: News Medical highlights Wei Wang's paper on 3q26.2 rearrangement in CML.
Sept. 2015 - Award: Wei Wang receives Best Poster Award, 3rd Place, at Society of Hematologic Oncology Annual Meeting, September 16-19, 2015, Houston, TX for "inv(3) in CML".
May 2013 – Award: Shimin Hu receives The Kimberly Patterson Endowed Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center, May 3, 2013.
May 2013 – Publication: Shimin Hu publishes paper "MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures" in Blood.
May 2013 - Highlight: MYC/BCL2 paper is selected as the plenary paper/CME article in Blood.
Apr. 2013 – Publication: Shimin Hu publishes paper "CD30-expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature" in Blood.
Apr. 2013 - Highlight: Blood highlights CD30 paper.
Mar 2013 – Award: Shimin Hu receives CAPA-GoPath Best Abstract Award, 1st Place, at USCAP-2013, March 2-8, 2013, Baltimore, MD for "CD30 in DLBCL" (USCAP platform presentation)
Oct. 2012 - Award: Shimin Hu receives Best Poster Award, 3rd Place, at Society of Hematologic Oncology Annual Meeting, October 10-14, 2012, Houston, TX for "MYC/BCL2 in DLBCL".
Jul. 2019 – Editorial Board: Shimin Hu joins the Editorial Board of Frontiers in Oncology as an Associate Editor for Hematologic Malignancies
Mar. 2018 - Highlight: JNCCN highlights Zimu Gong's paper on cytogenetics-based risk prediction of blastic transformation of CML.
Feb. 2018 – Editorial Boards: Shimin Hu joins the Editorial Boards of American Journal of Clinical pathology and Leukemia Research
Dec. 2017 – Publication: Habibe Kurt (clinical fellow) publishes paper "Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome" in Modern Pathology.
Dec. 2017 - Publication: Zimu Gong publishes paper "Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors" in Blood Advances.
Nov. 2017 - Award: Zimu Gong (visiting PhD student) receives ASH Abstract Achievement Award, 59th ASH Annual Meeting, Atlanta, GA for "Prediction of blastic transformation of CML" (ASH oral presentation)
Jul. 2017 - Publication: Zimu Gong publishes paper "Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia" in Blood Cancer Journal.
May 2017 – Award: Zhihong Hu (clinical fellow) receives The Shannon Timmins Fellowship for Leukemia Research, The University of Texas MD Anderson Cancer Center, May 3, 2017
Mar. 2017 - Publication: Zi Chen (visiting associate professor) publishes paper "Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy" in Leukemia.
Sept. 2016 - Highlight: MD Anderson Cancer Center spotlights Zi Chen's paper on cytogenetic landscape of CML-BP.
Oct. 2016 - Highlight: iCMLf highlights Zi Chen's paper on cytogenetic landscape of CML-BP.
Feb. 2017 - Publication: Zi Chen publishes paper "Differential depth of treatment response required for optimal outcome in blast phase versus chronic phase of chronic myeloid leukemia" in Blood Cancer Journal. This study could provide a basis for establishing a guideline in the management of patients with CML-BP.
Jul. 2016 - Publication: Zi Chen publishes paper "Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy" in Leukemia.
May 2016 - Publication: Zi Chen publishes paper "Differential clinical and prognostic impact of myeloid sarcoma versus medullary myeloid blast phase in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy" in Blood Cancer Journal.
Jun. 2016 - Award: Kristina Regimi (MS student) receives 2016 AGT Student Research Award at AGT 41st Annual Meeting, June 23-25, 2016, Orange County, CA for "MYC rearrangement in PCM" (only one student awarded nationally every year).
Jun. 2016 – Publication: Wei Wang (clinical fellow) publishes paper "Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy" in Blood.
Jun. 2016 - Highlight: Blood highlights Wei Wang's paper on risk stratification of CML.
Apr. 2016 - Highlight: iCMLf highlights Wei Wang's paper on risk stratification of CML.
May 2016 – Award: Wei Wang receives The Kimberly Patterson Endowed Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center, May 20, 2016.
Mar. 2016 - Award: Wei Wang receives CAPA-GoPath Best Abstract Award, 1st Place, at USCAP-2016, March 12-18, 2016, Seattle, WA for "Risk Stratification of CML".
Jan. 2016 - Award: Wei Wang receives Platform Competition, 1st Place at Texas Society of Pathologists Annual Meeting, Jan 17, 2016, Dallas, TX for "Risk Stratification of CML".
Nov. 2015 - Publication: Wei Wang publishes paper "Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in era of tyrosine kinase inhibitors" in Leukemia.
Oct. 2015 – Publication: Wei Wang publishes paper "Clinical and prognostic significance of 3q26.2 rearrangements and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors" in Blood.
Oct. 2015 - Highlight: MDedge Hematology News highlights Wei Wang's paper on 3q26.2 rearrangement in CML.
Oct. 2015 - Highlight: News Medical highlights Wei Wang's paper on 3q26.2 rearrangement in CML.
Sept. 2015 - Award: Wei Wang receives Best Poster Award, 3rd Place, at Society of Hematologic Oncology Annual Meeting, September 16-19, 2015, Houston, TX for "inv(3) in CML".
May 2013 – Award: Shimin Hu receives The Kimberly Patterson Endowed Fellowship in Leukemia Research, The University of Texas MD Anderson Cancer Center, May 3, 2013.
May 2013 – Publication: Shimin Hu publishes paper "MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures" in Blood.
May 2013 - Highlight: MYC/BCL2 paper is selected as the plenary paper/CME article in Blood.
Apr. 2013 – Publication: Shimin Hu publishes paper "CD30-expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature" in Blood.
Apr. 2013 - Highlight: Blood highlights CD30 paper.
Mar 2013 – Award: Shimin Hu receives CAPA-GoPath Best Abstract Award, 1st Place, at USCAP-2013, March 2-8, 2013, Baltimore, MD for "CD30 in DLBCL" (USCAP platform presentation)
Oct. 2012 - Award: Shimin Hu receives Best Poster Award, 3rd Place, at Society of Hematologic Oncology Annual Meeting, October 10-14, 2012, Houston, TX for "MYC/BCL2 in DLBCL".